3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Racial and Ethnic Disparities in All-Cause and Cardiovascular Mortality Among Cancer Patients in the U.S.

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          With improved cancer survival, death from noncancer etiologies, especially cardiovascular disease (CVD) mortality, has come more into focus. Little is known about the racial and ethnic disparities in all-cause and CVD mortality among U.S. cancer patients.

          Objectives

          This study sought to investigate racial and ethnic disparities in all-cause and CVD mortality among adults with cancer in the United States.

          Methods

          Using the Surveillance, Epidemiology, and End Results (SEER) database from years 2000 to 2018, all-cause and CVD mortality among patients ≥18 years of age at the time of initial malignancy diagnosis were compared by race and ethnicity groups. The 10 most prevalent cancers were included. Cox regression models were used to estimate adjusted HRs for all-cause and CVD mortality using Fine and Gray’s method for competing risks, as applicable.

          Results

          Among a total of 3,674,511 participants included in our study, 1,644,067 (44.7%) died, with 231,386 (6.3%) deaths as a result of CVD. After adjusting for sociodemographic and clinical characteristics, non-Hispanic (NH) Black individuals had both higher all-cause (HR: 1.13; 95% CI: 1.13-1.14) and CVD (HR: 1.25; 95% CI: 1.24-1.27) mortality, whereas Hispanic and NH Asian/Pacific Islander had lower mortality than NH White patients. Racial and ethnic disparities were more prominent among patients 18 to 54 years of age and those with localized cancer.

          Conclusions

          Significant racial and ethnic differences exist in both all-cause and CVD mortality among U.S. cancer patients. Our findings underscore the vital roles of accessible cardiovascular interventions and strategies to identify high-risk cancer populations who may benefit most from early and long-term survivorship care.

          Central Illustration

          Related collections

          Most cited references37

          • Record: found
          • Abstract: found
          • Article: not found

          Cancer Statistics, 2021

          Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence. Incidence data (through 2017) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2018) were collected by the National Center for Health Statistics. In 2021, 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the United States. After increasing for most of the 20th century, the cancer death rate has fallen continuously from its peak in 1991 through 2018, for a total decline of 31%, because of reductions in smoking and improvements in early detection and treatment. This translates to 3.2 million fewer cancer deaths than would have occurred if peak rates had persisted. Long-term declines in mortality for the 4 leading cancers have halted for prostate cancer and slowed for breast and colorectal cancers, but accelerated for lung cancer, which accounted for almost one-half of the total mortality decline from 2014 to 2018. The pace of the annual decline in lung cancer mortality doubled from 3.1% during 2009 through 2013 to 5.5% during 2014 through 2018 in men, from 1.8% to 4.4% in women, and from 2.4% to 5% overall. This trend coincides with steady declines in incidence (2.2%-2.3%) but rapid gains in survival specifically for nonsmall cell lung cancer (NSCLC). For example, NSCLC 2-year relative survival increased from 34% for persons diagnosed during 2009 through 2010 to 42% during 2015 through 2016, including absolute increases of 5% to 6% for every stage of diagnosis; survival for small cell lung cancer remained at 14% to 15%. Improved treatment accelerated progress against lung cancer and drove a record drop in overall cancer mortality, despite slowing momentum for other common cancers.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cardiovascular Health in African Americans: A Scientific Statement From the American Heart Association

            Population-wide reductions in cardiovascular disease incidence and mortality have not been shared equally by African Americans. The burden of cardiovascular disease in the African American community remains high and is a primary cause of disparities in life expectancy between African Americans and whites. The objectives of the present scientific statement are to describe cardiovascular health in African Americans and to highlight unique considerations for disease prevention and management.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Shared Risk Factors in Cardiovascular Disease and Cancer.

              Cardiovascular disease (CVD) and cancer are the 2 leading causes of death worldwide. Although commonly thought of as 2 separate disease entities, CVD and cancer possess various similarities and possible interactions, including a number of similar risk factors (eg, obesity, diabetes mellitus), suggesting a shared biology for which there is emerging evidence. Although chronic inflammation is an indispensable feature of the pathogenesis and progression of both CVD and cancer, additional mechanisms can be found at their intersection. Therapeutic advances, despite improving longevity, have increased the overlap between these diseases, with millions of cancer survivors now at risk of developing CVD. Cardiac risk factors have a major impact on subsequent treatment-related cardiotoxicity. In this review, we explore the risk factors common to both CVD and cancer, highlighting the major epidemiological studies and potential biological mechanisms that account for them.
                Bookmark

                Author and article information

                Contributors
                Journal
                JACC CardioOncol
                JACC CardioOncol
                JACC: CardioOncology
                Elsevier
                2666-0873
                21 February 2023
                February 2023
                21 February 2023
                : 5
                : 1
                : 55-66
                Affiliations
                [a ]Department of Chronic Disease Epidemiology, Yale University, New Haven, Connecticut, USA
                [b ]Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
                [c ]Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
                [d ]Division of Cardiology, Department of Internal Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA
                [e ]Division of Cardiovascular Medicine, Bridgeport Hospital, Yale New Haven Health System, Bridgeport, Connecticut, USA
                Author notes
                [] Address for correspondence: Dr Stuart Zarich, Division of Cardiovascular Medicine, Bridgeport Hospital, Yale New Haven Health System, 267 Grant Street, Bridgeport, Connecticut 06610, USA. dr.stuart.zarich@ 123456bpthosp.org
                [∗]

                Drs Zhu and Shi contributed equally to this work and are co-first authors.

                Article
                S2666-0873(23)00005-4
                10.1016/j.jaccao.2022.10.013
                9982284
                36875907
                32f4248a-4419-43eb-a4bd-69d3a0dfee73
                © 2023 The Authors

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 31 May 2022
                : 11 October 2022
                : 18 October 2022
                Categories
                Original Research

                cancer survivorship,cardio-oncology,outcomes,racial and ethnic disparities,cvd, cardiovascular disease,seer, surveillance, epidemiology, and end results,nh, non-hispanic

                Comments

                Comment on this article